JP2019511920A - 活性薬剤の蒸発及び吸入装置 - Google Patents
活性薬剤の蒸発及び吸入装置 Download PDFInfo
- Publication number
- JP2019511920A JP2019511920A JP2018545487A JP2018545487A JP2019511920A JP 2019511920 A JP2019511920 A JP 2019511920A JP 2018545487 A JP2018545487 A JP 2018545487A JP 2018545487 A JP2018545487 A JP 2018545487A JP 2019511920 A JP2019511920 A JP 2019511920A
- Authority
- JP
- Japan
- Prior art keywords
- carrier material
- deliverable
- nicotine
- deliverable agent
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims description 73
- 229940079593 drug Drugs 0.000 title claims description 61
- 238000001704 evaporation Methods 0.000 title claims description 15
- 230000008020 evaporation Effects 0.000 title claims description 14
- 239000012876 carrier material Substances 0.000 claims abstract description 237
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 192
- 239000000463 material Substances 0.000 claims abstract description 147
- 239000011148 porous material Substances 0.000 claims abstract description 132
- 239000008186 active pharmaceutical agent Substances 0.000 claims abstract description 65
- 229920000876 geopolymer Polymers 0.000 claims abstract description 41
- 239000000443 aerosol Substances 0.000 claims abstract description 22
- 239000007787 solid Substances 0.000 claims abstract description 21
- 238000010438 heat treatment Methods 0.000 claims description 153
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 126
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 123
- 229960002715 nicotine Drugs 0.000 claims description 122
- 238000000034 method Methods 0.000 claims description 96
- 239000000203 mixture Substances 0.000 claims description 96
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 90
- 239000002245 particle Substances 0.000 claims description 48
- 239000007788 liquid Substances 0.000 claims description 46
- 239000000126 substance Substances 0.000 claims description 39
- 238000009472 formulation Methods 0.000 claims description 38
- 239000002243 precursor Substances 0.000 claims description 34
- 229910052751 metal Inorganic materials 0.000 claims description 33
- 239000002184 metal Substances 0.000 claims description 32
- 239000004020 conductor Substances 0.000 claims description 30
- 230000008569 process Effects 0.000 claims description 30
- 229910010293 ceramic material Inorganic materials 0.000 claims description 29
- 239000000014 opioid analgesic Substances 0.000 claims description 28
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 27
- 208000002193 Pain Diseases 0.000 claims description 23
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 21
- 229940005483 opioid analgesics Drugs 0.000 claims description 20
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 17
- 230000036407 pain Effects 0.000 claims description 17
- 229910000323 aluminium silicate Inorganic materials 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 15
- 206010057852 Nicotine dependence Diseases 0.000 claims description 14
- 208000025569 Tobacco Use disease Diseases 0.000 claims description 14
- 150000002739 metals Chemical class 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 10
- 239000000730 antalgic agent Substances 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 239000000377 silicon dioxide Substances 0.000 claims description 10
- 235000011010 calcium phosphates Nutrition 0.000 claims description 9
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 9
- HPTYUNKZVDYXLP-UHFFFAOYSA-N aluminum;trihydroxy(trihydroxysilyloxy)silane;hydrate Chemical compound O.[Al].[Al].O[Si](O)(O)O[Si](O)(O)O HPTYUNKZVDYXLP-UHFFFAOYSA-N 0.000 claims description 8
- 239000001506 calcium phosphate Substances 0.000 claims description 8
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 8
- 239000000378 calcium silicate Substances 0.000 claims description 8
- 229910052918 calcium silicate Inorganic materials 0.000 claims description 8
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 claims description 8
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 8
- 239000005995 Aluminium silicate Substances 0.000 claims description 7
- 235000012211 aluminium silicate Nutrition 0.000 claims description 7
- XFWJKVMFIVXPKK-UHFFFAOYSA-N calcium;oxido(oxo)alumane Chemical compound [Ca+2].[O-][Al]=O.[O-][Al]=O XFWJKVMFIVXPKK-UHFFFAOYSA-N 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000003623 enhancer Substances 0.000 claims description 6
- 229960002428 fentanyl Drugs 0.000 claims description 6
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims description 6
- 229910052621 halloysite Inorganic materials 0.000 claims description 6
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 claims description 5
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 5
- 239000000932 sedative agent Substances 0.000 claims description 5
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims description 4
- 229910001649 dickite Inorganic materials 0.000 claims description 4
- 239000003326 hypnotic agent Substances 0.000 claims description 4
- 229910052900 illite Inorganic materials 0.000 claims description 4
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 4
- 239000001095 magnesium carbonate Substances 0.000 claims description 4
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 4
- 229960005181 morphine Drugs 0.000 claims description 4
- VGIBGUSAECPPNB-UHFFFAOYSA-L nonaaluminum;magnesium;tripotassium;1,3-dioxido-2,4,5-trioxa-1,3-disilabicyclo[1.1.1]pentane;iron(2+);oxygen(2-);fluoride;hydroxide Chemical compound [OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[F-].[Mg+2].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[K+].[K+].[K+].[Fe+2].O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2 VGIBGUSAECPPNB-UHFFFAOYSA-L 0.000 claims description 4
- 229960002085 oxycodone Drugs 0.000 claims description 4
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 claims description 3
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 claims description 3
- 229910021536 Zeolite Inorganic materials 0.000 claims description 3
- 229960001391 alfentanil Drugs 0.000 claims description 3
- 239000002220 antihypertensive agent Substances 0.000 claims description 3
- 229960001736 buprenorphine Drugs 0.000 claims description 3
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims description 3
- 239000003205 fragrance Substances 0.000 claims description 3
- 230000000147 hypnotic effect Effects 0.000 claims description 3
- 229960003394 remifentanil Drugs 0.000 claims description 3
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims description 3
- 229960004739 sufentanil Drugs 0.000 claims description 3
- 239000010457 zeolite Substances 0.000 claims description 3
- 230000001624 sedative effect Effects 0.000 claims description 2
- 230000003276 anti-hypertensive effect Effects 0.000 claims 1
- 239000000919 ceramic Substances 0.000 abstract description 72
- 239000004480 active ingredient Substances 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- 239000000523 sample Substances 0.000 description 35
- 239000000243 solution Substances 0.000 description 33
- -1 nacrite Chemical compound 0.000 description 31
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 30
- 239000000843 powder Substances 0.000 description 29
- 229960000658 sumatriptan succinate Drugs 0.000 description 29
- ZNIFSRGNXRYGHF-UHFFFAOYSA-N Clonidine hydrochloride Chemical compound Cl.ClC1=CC=CC(Cl)=C1NC1=NCCN1 ZNIFSRGNXRYGHF-UHFFFAOYSA-N 0.000 description 26
- 229960002925 clonidine hydrochloride Drugs 0.000 description 26
- 229910001868 water Inorganic materials 0.000 description 23
- 239000007789 gas Substances 0.000 description 19
- 239000013074 reference sample Substances 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 17
- 230000006698 induction Effects 0.000 description 17
- 239000008367 deionised water Substances 0.000 description 14
- 229910021641 deionized water Inorganic materials 0.000 description 14
- 239000003571 electronic cigarette Substances 0.000 description 14
- 239000008188 pellet Substances 0.000 description 14
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 13
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 13
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 238000005245 sintering Methods 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000008187 granular material Substances 0.000 description 10
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 9
- 239000003570 air Substances 0.000 description 9
- 229910052782 aluminium Inorganic materials 0.000 description 9
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 9
- 239000004568 cement Substances 0.000 description 9
- 229960001680 ibuprofen Drugs 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 229910004298 SiO 2 Inorganic materials 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000013543 active substance Substances 0.000 description 7
- 230000000202 analgesic effect Effects 0.000 description 7
- 239000000945 filler Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 6
- 229910045601 alloy Inorganic materials 0.000 description 6
- 239000000956 alloy Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000000227 grinding Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 229910052742 iron Inorganic materials 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 238000005453 pelletization Methods 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 229920002379 silicone rubber Polymers 0.000 description 6
- 239000004945 silicone rubber Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 229910052719 titanium Inorganic materials 0.000 description 6
- 239000010936 titanium Substances 0.000 description 6
- 230000008016 vaporization Effects 0.000 description 6
- 238000010146 3D printing Methods 0.000 description 5
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000003557 cannabinoid Substances 0.000 description 5
- 229930003827 cannabinoid Natural products 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 5
- 229920001971 elastomer Polymers 0.000 description 5
- 229910021485 fumed silica Inorganic materials 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 229940127240 opiate Drugs 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 230000000391 smoking effect Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 208000000094 Chronic Pain Diseases 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 229940035676 analgesics Drugs 0.000 description 4
- 239000000729 antidote Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 235000005687 corn oil Nutrition 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 229940088679 drug related substance Drugs 0.000 description 4
- 238000005187 foaming Methods 0.000 description 4
- 230000036571 hydration Effects 0.000 description 4
- 238000006703 hydration reaction Methods 0.000 description 4
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 150000004767 nitrides Chemical class 0.000 description 4
- 229940121367 non-opioid analgesics Drugs 0.000 description 4
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000003361 porogen Substances 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 239000011253 protective coating Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 229940125723 sedative agent Drugs 0.000 description 4
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 241000218236 Cannabis Species 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 3
- 244000061176 Nicotiana tabacum Species 0.000 description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 3
- 102000003840 Opioid Receptors Human genes 0.000 description 3
- 108090000137 Opioid Receptors Proteins 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229910052581 Si3N4 Inorganic materials 0.000 description 3
- 239000004115 Sodium Silicate Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229910000831 Steel Inorganic materials 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 3
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 3
- 229910052750 molybdenum Inorganic materials 0.000 description 3
- 239000011733 molybdenum Substances 0.000 description 3
- 229910052759 nickel Inorganic materials 0.000 description 3
- 229910052574 oxide ceramic Inorganic materials 0.000 description 3
- 239000011224 oxide ceramic Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000011164 primary particle Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 150000004760 silicates Chemical class 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 3
- 229910010271 silicon carbide Inorganic materials 0.000 description 3
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052911 sodium silicate Inorganic materials 0.000 description 3
- 238000003980 solgel method Methods 0.000 description 3
- 239000010959 steel Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 230000009747 swallowing Effects 0.000 description 3
- 229910052715 tantalum Inorganic materials 0.000 description 3
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052726 zirconium Inorganic materials 0.000 description 3
- 229910001928 zirconium oxide Inorganic materials 0.000 description 3
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 2
- GIKNHHRFLCDOEU-UHFFFAOYSA-N 4-(2-aminopropyl)phenol Chemical compound CC(N)CC1=CC=C(O)C=C1 GIKNHHRFLCDOEU-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- 229910000838 Al alloy Inorganic materials 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- ZCTQGTTXIYCGGC-UHFFFAOYSA-N Benzyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 ZCTQGTTXIYCGGC-UHFFFAOYSA-N 0.000 description 2
- 229910001369 Brass Inorganic materials 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229910000570 Cupronickel Inorganic materials 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- DEXMFYZAHXMZNM-UHFFFAOYSA-N Narceine Chemical compound OC(=O)C1=C(OC)C(OC)=CC=C1C(=O)CC1=C(CCN(C)C)C=C(OCO2)C2=C1OC DEXMFYZAHXMZNM-UHFFFAOYSA-N 0.000 description 2
- ONBWJWYUHXVEJS-ZTYRTETDSA-N Normorphine Chemical compound C([C@@H](NCC1)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ONBWJWYUHXVEJS-ZTYRTETDSA-N 0.000 description 2
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229910001069 Ti alloy Inorganic materials 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127090 anticoagulant agent Drugs 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 238000000498 ball milling Methods 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000010951 brass Substances 0.000 description 2
- 230000001680 brushing effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- ZOMBKNNSYQHRCA-UHFFFAOYSA-J calcium sulfate hemihydrate Chemical compound O.[Ca+2].[Ca+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O ZOMBKNNSYQHRCA-UHFFFAOYSA-J 0.000 description 2
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000012700 ceramic precursor Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960004126 codeine Drugs 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- YOCUPQPZWBBYIX-UHFFFAOYSA-N copper nickel Chemical compound [Ni].[Cu] YOCUPQPZWBBYIX-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000000280 densification Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229960002069 diamorphine Drugs 0.000 description 2
- 229960000920 dihydrocodeine Drugs 0.000 description 2
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 2
- 238000005906 dihydroxylation reaction Methods 0.000 description 2
- 238000003618 dip coating Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 2
- 229960000240 hydrocodone Drugs 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229910052622 kaolinite Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 230000005291 magnetic effect Effects 0.000 description 2
- 239000000696 magnetic material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 150000001247 metal acetylides Chemical class 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 102000051367 mu Opioid Receptors Human genes 0.000 description 2
- 229910000623 nickel–chromium alloy Inorganic materials 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 229950006134 normorphine Drugs 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229960000482 pethidine Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 238000005563 spheronization Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 229960003708 sumatriptan Drugs 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 2
- 230000007723 transport mechanism Effects 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 239000011364 vaporized material Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 108020001612 μ-opioid receptors Proteins 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- YQYVFVRQLZMJKJ-JBBXEZCESA-N (+)-cyclazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CC1CC1 YQYVFVRQLZMJKJ-JBBXEZCESA-N 0.000 description 1
- FJIKWRGCXUCUIG-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C([C@H](O)N=1)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1Cl FJIKWRGCXUCUIG-HNNXBMFYSA-N 0.000 description 1
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- QBWLKDFBINPHFT-UHFFFAOYSA-L 1,3,2$l^{2}-benzodioxabismin-4-one;hydrate Chemical compound O.C1=CC=C2C(=O)O[Bi]OC2=C1 QBWLKDFBINPHFT-UHFFFAOYSA-L 0.000 description 1
- OYRPNABWTHDOFK-UHFFFAOYSA-N 1-methyl-8-nitro-6-phenyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine Chemical compound C12=CC([N+]([O-])=O)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 OYRPNABWTHDOFK-UHFFFAOYSA-N 0.000 description 1
- LLSKXGRDUPMXLC-UHFFFAOYSA-N 1-phenylpiperidine Chemical compound C1CCCCN1C1=CC=CC=C1 LLSKXGRDUPMXLC-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 1
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- KISZTEOELCMZPY-UHFFFAOYSA-N 3,3-diphenylpropylamine Chemical class C=1C=CC=CC=1C(CCN)C1=CC=CC=C1 KISZTEOELCMZPY-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- XBWAZCLHZCFCGK-UHFFFAOYSA-N 7-chloro-1-methyl-5-phenyl-3,4-dihydro-2h-1,4-benzodiazepin-1-ium;chloride Chemical compound [Cl-].C12=CC(Cl)=CC=C2[NH+](C)CCN=C1C1=CC=CC=C1 XBWAZCLHZCFCGK-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004604 Blowing Agent Substances 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 208000000003 Breakthrough pain Diseases 0.000 description 1
- VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000005698 Diels-Alder reaction Methods 0.000 description 1
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N Ethyl salicylate Chemical compound CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- OGDVEMNWJVYAJL-UHFFFAOYSA-N Ethylmorphine Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OCC OGDVEMNWJVYAJL-UHFFFAOYSA-N 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- ALFGKMXHOUSVAD-UHFFFAOYSA-N Ketobemidone Chemical compound C=1C=CC(O)=CC=1C1(C(=O)CC)CCN(C)CC1 ALFGKMXHOUSVAD-UHFFFAOYSA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- OZYUPQUCAUTOBP-QXAKKESOSA-N Levallorphan Chemical compound C([C@H]12)CCC[C@@]11CCN(CC=C)[C@@H]2CC2=CC=C(O)C=C21 OZYUPQUCAUTOBP-QXAKKESOSA-N 0.000 description 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
- ZPVWYKDNUXVATR-UHFFFAOYSA-L S(=O)(=O)([O-])[O-].[Ca+2].N1=CC=CC(=C1)C1N(C)CCC1 Chemical compound S(=O)(=O)([O-])[O-].[Ca+2].N1=CC=CC(=C1)C1N(C)CCC1 ZPVWYKDNUXVATR-UHFFFAOYSA-L 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229940116731 Uricosuric agent Drugs 0.000 description 1
- UVAZQQHAVMNMHE-BBRMVZONSA-N [(3s,4s)-1,3-dimethyl-4-phenylpiperidin-4-yl] propanoate Chemical compound C=1C=CC=CC=1[C@]1(OC(=O)CC)CCN(C)C[C@@H]1C UVAZQQHAVMNMHE-BBRMVZONSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000004964 aerogel Substances 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 150000004645 aluminates Chemical class 0.000 description 1
- ANBBXQWFNXMHLD-UHFFFAOYSA-N aluminum;sodium;oxygen(2-) Chemical compound [O-2].[O-2].[Na+].[Al+3] ANBBXQWFNXMHLD-UHFFFAOYSA-N 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000010828 animal waste Substances 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 239000000059 antiamebic agent Substances 0.000 description 1
- 229940124346 antiarthritic agent Drugs 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000030 antiglaucoma agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000013059 antihormonal agent Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000003716 antitrichomonal agent Substances 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229940051805 benzomorphan derivative analgesics Drugs 0.000 description 1
- RDJGWRFTDZZXSM-RNWLQCGYSA-N benzylmorphine Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1OCC1=CC=CC=C1 RDJGWRFTDZZXSM-RNWLQCGYSA-N 0.000 description 1
- 229950000011 betaprodine Drugs 0.000 description 1
- 229960000782 bismuth subsalicylate Drugs 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960002729 bromazepam Drugs 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 229960000926 camazepam Drugs 0.000 description 1
- PXBVEXGRHZFEOF-UHFFFAOYSA-N camazepam Chemical compound C12=CC(Cl)=CC=C2N(C)C(=O)C(OC(=O)N(C)C)N=C1C1=CC=CC=C1 PXBVEXGRHZFEOF-UHFFFAOYSA-N 0.000 description 1
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 1
- 229950011318 cannabidiol Drugs 0.000 description 1
- 229960003453 cannabinol Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 229950004689 carfentanil Drugs 0.000 description 1
- YDSDEBIZUNNPOB-UHFFFAOYSA-N carfentanil Chemical compound C1CN(CCC=2C=CC=CC=2)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 YDSDEBIZUNNPOB-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003576 central nervous system agent Substances 0.000 description 1
- 229940125693 central nervous system agent Drugs 0.000 description 1
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000000788 chromium alloy Substances 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000002734 clay mineral Substances 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 239000011362 coarse particle Substances 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 238000012669 compression test Methods 0.000 description 1
- 239000004567 concrete Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000009770 conventional sintering Methods 0.000 description 1
- CMDYHTIDHSNRGW-UHFFFAOYSA-L copper;2-acetyloxybenzoate Chemical compound [Cu+2].CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O CMDYHTIDHSNRGW-UHFFFAOYSA-L 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 229950002213 cyclazocine Drugs 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 description 1
- 229950003851 desomorphine Drugs 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 229960003701 dextromoramide Drugs 0.000 description 1
- INUNXTSAACVKJS-OAQYLSRUSA-N dextromoramide Chemical compound C([C@@H](C)C(C(=O)N1CCCC1)(C=1C=CC=CC=1)C=1C=CC=CC=1)N1CCOCC1 INUNXTSAACVKJS-OAQYLSRUSA-N 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 229960003461 dezocine Drugs 0.000 description 1
- VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 1
- RHUWRJWFHUKVED-UHFFFAOYSA-N dimenoxadol Chemical compound C=1C=CC=CC=1C(C(=O)OCCN(C)C)(OCC)C1=CC=CC=C1 RHUWRJWFHUKVED-UHFFFAOYSA-N 0.000 description 1
- 229950011187 dimenoxadol Drugs 0.000 description 1
- 229960004192 diphenoxylate Drugs 0.000 description 1
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
- 229940051806 diphenylpropylamine derivative analgesics Drugs 0.000 description 1
- SVDHSZFEQYXRDC-UHFFFAOYSA-N dipipanone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CC(C)N1CCCCC1 SVDHSZFEQYXRDC-UHFFFAOYSA-N 0.000 description 1
- 229960002500 dipipanone Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000009837 dry grinding Methods 0.000 description 1
- QIQNNBXHAYSQRY-UYXSQOIJSA-N ecgonine methyl ester Chemical compound C1[C@H](O)[C@H](C(=O)OC)[C@H]2CC[C@@H]1N2C QIQNNBXHAYSQRY-UYXSQOIJSA-N 0.000 description 1
- QIQNNBXHAYSQRY-UHFFFAOYSA-N ecgonine methyl ester Natural products C1C(O)C(C(=O)OC)C2CCC1N2C QIQNNBXHAYSQRY-UHFFFAOYSA-N 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- ZOWQTJXNFTWSCS-IAQYHMDHSA-N eptazocine Chemical compound C1N(C)CC[C@@]2(C)C3=CC(O)=CC=C3C[C@@H]1C2 ZOWQTJXNFTWSCS-IAQYHMDHSA-N 0.000 description 1
- 229950010920 eptazocine Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229960002336 estazolam Drugs 0.000 description 1
- CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 description 1
- 229960001578 eszopiclone Drugs 0.000 description 1
- GBBSUAFBMRNDJC-INIZCTEOSA-N eszopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-INIZCTEOSA-N 0.000 description 1
- 229940005667 ethyl salicylate Drugs 0.000 description 1
- 229960004578 ethylmorphine Drugs 0.000 description 1
- PXDBZSCGSQSKST-UHFFFAOYSA-N etonitazene Chemical compound C1=CC(OCC)=CC=C1CC1=NC2=CC([N+]([O-])=O)=CC=C2N1CCN(CC)CC PXDBZSCGSQSKST-UHFFFAOYSA-N 0.000 description 1
- 229950004538 etonitazene Drugs 0.000 description 1
- 229950004155 etorphine Drugs 0.000 description 1
- CAHCBJPUTCKATP-FAWZKKEFSA-N etorphine Chemical compound O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O CAHCBJPUTCKATP-FAWZKKEFSA-N 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000005293 ferrimagnetic effect Effects 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229960004930 fludiazepam Drugs 0.000 description 1
- ROYOYTLGDLIGBX-UHFFFAOYSA-N fludiazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F ROYOYTLGDLIGBX-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002200 flunitrazepam Drugs 0.000 description 1
- 229960003528 flurazepam Drugs 0.000 description 1
- SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 229960002158 halazepam Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229960004881 homosalate Drugs 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 238000001513 hot isostatic pressing Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229950005360 hydroxyamfetamine Drugs 0.000 description 1
- WTJBNMUWRKPFRS-UHFFFAOYSA-N hydroxypethidine Chemical compound C=1C=CC(O)=CC=1C1(C(=O)OCC)CCN(C)CC1 WTJBNMUWRKPFRS-UHFFFAOYSA-N 0.000 description 1
- 229950008496 hydroxypethidine Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229920000592 inorganic polymer Polymers 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- IFKPLJWIEQBPGG-UHFFFAOYSA-N isomethadone Chemical compound C=1C=CC=CC=1C(C(C)CN(C)C)(C(=O)CC)C1=CC=CC=C1 IFKPLJWIEQBPGG-UHFFFAOYSA-N 0.000 description 1
- 229950009272 isomethadone Drugs 0.000 description 1
- 238000010902 jet-milling Methods 0.000 description 1
- 229960003029 ketobemidone Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- XBMIVRRWGCYBTQ-AVRDEDQJSA-N levacetylmethadol Chemical compound C=1C=CC=CC=1C(C[C@H](C)N(C)C)([C@@H](OC(C)=O)CC)C1=CC=CC=C1 XBMIVRRWGCYBTQ-AVRDEDQJSA-N 0.000 description 1
- 229960000263 levallorphan Drugs 0.000 description 1
- 229940087121 levomethadyl Drugs 0.000 description 1
- 229960003406 levorphanol Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- IMYHGORQCPYVBZ-NLFFAJNJSA-N lofentanil Chemical compound CCC(=O)N([C@@]1([C@@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 IMYHGORQCPYVBZ-NLFFAJNJSA-N 0.000 description 1
- 229950010274 lofentanil Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 229960004033 lormetazepam Drugs 0.000 description 1
- 229940072082 magnesium salicylate Drugs 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- FQXXSQDCDRQNQE-UHFFFAOYSA-N markiertes Thebain Natural products COC1=CC=C2C(N(CC3)C)CC4=CC=C(OC)C5=C4C23C1O5 FQXXSQDCDRQNQE-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960002225 medazepam Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 239000006262 metallic foam Substances 0.000 description 1
- 229910052752 metalloid Inorganic materials 0.000 description 1
- 150000002738 metalloids Chemical class 0.000 description 1
- YEOTYALSMRNXLJ-UHFFFAOYSA-N metazosin Chemical compound C1CN(C(=O)C(C)OC)CCN1C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 YEOTYALSMRNXLJ-UHFFFAOYSA-N 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 229960001165 modafinil Drugs 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- INAXVFBXDYWQFN-XHSDSOJGSA-N morphinan Chemical class C1C2=CC=CC=C2[C@]23CCCC[C@H]3[C@@H]1NCC2 INAXVFBXDYWQFN-XHSDSOJGSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229960000805 nalbuphine Drugs 0.000 description 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
- 229960000938 nalorphine Drugs 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960004300 nicomorphine Drugs 0.000 description 1
- HNDXBGYRMHRUFN-CIVUWBIHSA-N nicomorphine Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)OC(=O)C=4C=NC=CC=4)O[C@@H]1[C@]52CCN3C)C(=O)C1=CC=CN=C1 HNDXBGYRMHRUFN-CIVUWBIHSA-N 0.000 description 1
- 229960001454 nitrazepam Drugs 0.000 description 1
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 229940124637 non-opioid analgesic drug Drugs 0.000 description 1
- 229910052755 nonmetal Inorganic materials 0.000 description 1
- 150000002843 nonmetals Chemical class 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- WCDSHELZWCOTMI-UHFFFAOYSA-N norpipanone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CCN1CCCCC1 WCDSHELZWCOTMI-UHFFFAOYSA-N 0.000 description 1
- 229950007418 norpipanone Drugs 0.000 description 1
- 229960003921 octisalate Drugs 0.000 description 1
- WCJLCOAEJIHPCW-UHFFFAOYSA-N octyl 2-hydroxybenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1O WCJLCOAEJIHPCW-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 229940051807 opiod analgesics morphinan derivative Drugs 0.000 description 1
- 229940124636 opioid drug Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940051877 other opioids in atc Drugs 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- LOXCOAXRHYDLOW-UHFFFAOYSA-N phenadoxone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CC(C)N1CCOCC1 LOXCOAXRHYDLOW-UHFFFAOYSA-N 0.000 description 1
- 229950004540 phenadoxone Drugs 0.000 description 1
- 150000002987 phenanthrenes Chemical class 0.000 description 1
- 229960000897 phenazocine Drugs 0.000 description 1
- ZQHYKVKNPWDQSL-KNXBSLHKSA-N phenazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CCC1=CC=CC=C1 ZQHYKVKNPWDQSL-KNXBSLHKSA-N 0.000 description 1
- 229960004315 phenoperidine Drugs 0.000 description 1
- IPOPQVVNCFQFRK-UHFFFAOYSA-N phenoperidine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(O)C1=CC=CC=C1 IPOPQVVNCFQFRK-UHFFFAOYSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- PXXKIYPSXYFATG-UHFFFAOYSA-N piminodine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCCNC1=CC=CC=C1 PXXKIYPSXYFATG-UHFFFAOYSA-N 0.000 description 1
- 229950006445 piminodine Drugs 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002459 porosimetry Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- FRMWBRPWYBNAFB-UHFFFAOYSA-M potassium salicylate Chemical compound [K+].OC1=CC=CC=C1C([O-])=O FRMWBRPWYBNAFB-UHFFFAOYSA-M 0.000 description 1
- 229960003629 potassium salicylate Drugs 0.000 description 1
- 235000019353 potassium silicate Nutrition 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000004663 powder metallurgy Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229950003779 propiram Drugs 0.000 description 1
- ZBAFFZBKCMWUHM-UHFFFAOYSA-N propiram Chemical compound C=1C=CC=NC=1N(C(=O)CC)C(C)CN1CCCCC1 ZBAFFZBKCMWUHM-UHFFFAOYSA-N 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000003870 refractory metal Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 229910000938 samarium–cobalt magnet Inorganic materials 0.000 description 1
- 229910052706 scandium Inorganic materials 0.000 description 1
- SIXSYDAISGFNSX-UHFFFAOYSA-N scandium atom Chemical compound [Sc] SIXSYDAISGFNSX-UHFFFAOYSA-N 0.000 description 1
- 239000003521 serotonin 5-HT1 receptor agonist Substances 0.000 description 1
- 229910021487 silica fume Inorganic materials 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 229910001388 sodium aluminate Inorganic materials 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 150000003444 succinic acids Chemical class 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 229930003945 thebaine Natural products 0.000 description 1
- FQXXSQDCDRQNQE-VMDGZTHMSA-N thebaine Chemical compound C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(OC)C5=C4[C@@]21[C@H]3O5 FQXXSQDCDRQNQE-VMDGZTHMSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 235000019505 tobacco product Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 239000003383 uricosuric agent Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
- HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 description 1
- 229960004010 zaleplon Drugs 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
- 229960000820 zopiclone Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
- A24F40/20—Devices using solid inhalable precursors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
- A24F40/40—Constructional details, e.g. connection of cartridges and battery parts
- A24F40/42—Cartridges or containers for inhalable precursors
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
- A24F40/40—Constructional details, e.g. connection of cartridges and battery parts
- A24F40/46—Shape or structure of electric heating means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
- A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
- A61M11/042—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters electrical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/1075—Preparation of respiratory gases or vapours by influencing the temperature
- A61M16/109—Preparation of respiratory gases or vapours by influencing the temperature the humidifying liquid or the beneficial agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
- A24F40/40—Constructional details, e.g. connection of cartridges and battery parts
- A24F40/46—Shape or structure of electric heating means
- A24F40/465—Shape or structure of electric heating means specially adapted for induction heating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0241—Anaesthetics; Analgesics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0211—Ceramics
-
- G—PHYSICS
- G05—CONTROLLING; REGULATING
- G05D—SYSTEMS FOR CONTROLLING OR REGULATING NON-ELECTRIC VARIABLES
- G05D23/00—Control of temperature
- G05D23/19—Control of temperature characterised by the use of electric means
- G05D23/20—Control of temperature characterised by the use of electric means with sensing elements having variation of electric or magnetic properties with change of temperature
- G05D23/24—Control of temperature characterised by the use of electric means with sensing elements having variation of electric or magnetic properties with change of temperature the sensing element having a resistance varying with temperature, e.g. a thermistor
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
(a)天然に存在するアヘンアルカロイド。これらには、モルヒネ及びコデインが含まれる。
(b)天然に存在するアルカロイドと化学構造が類似している化合物。これらのいわゆる半合成物は、天然に存在するアルカロイドの化学修飾によって生成され、ジアモルフィン(ヘロイン)、オキシコドン、及びヒドロコドンなどを含む。及び、
(c)真の合成化合物、例えばフェンタニル及びメタドン。このような化合物は、それらの化学構造に関して天然に存在する化合物とは全く異なっていてもよい。
(a)適切な溶離剤、例えば酸及び/又はアルコールを用いてその製剤から大量の活性成分を抽出して溶液を形成し、次いでそれを静脈内に注入。ほとんどの市販されている医薬製剤では、これは比較的簡単に行うことができ、それらを安全でないか、または「乱用可能」にする。
(b)加熱(そして喫煙)。
(c)錠剤を粉砕(そして吸引)。及び/又は、
(d)パッチの場合には、茶を作製(そして飲用)。
(i)少なくとも10%の気孔率を有する固体多孔質の担体材料と、
(ii)担体材料の気孔内に位置する、上記に定義された送達可能な薬剤と、を備える。
(i)少なくとも10%の気孔率を有する固体多孔質の担体材料と、
(ii)担体材料の気孔内に位置する、上記に定義された送達可能な薬剤と、
(iii)担体材料全体にわたって分布された導電性材料(例えば、金属)の粒子と、を備える。
(i)ケイ素、アルミニウム、炭素、チタン、ジルコニウムもしくはタンタル、及びそれらの組み合わせのいずれかの元素の酸化物、窒化物、及び/又は炭化物と、
(ii)アルミノケイ酸塩前駆体材料を水性アルカリ性液体と反応させるプロセスによって得ることができる材料と、
(iii)リン酸カルシウム、硫酸カルシウム、炭酸カルシウム、ケイ酸カルシウム、アルミン酸カルシウム、炭酸マグネシウム、ケイ酸アルミニウム、及びそれらの組み合わせと、
(iv)真鍮、マンガン、モリブデン、ニッケル、白金、亜鉛、チタン、チタン合金、ニッケル−クロム合金、銅−ニッケル合金、鉄、鋼、アルミニウム、及び鉄−クロム−アルミニウム合金と、からなる群より選択される、上記に記載の装置に関する。
i)錠剤を飲み込む前に噛むこと、
ii)胃腸管通過時の偶発的破壊、及び/又は
iii)生体外での改ざん、すなわち、処方された薬物の機能性の破壊をもたらし得る、その後の乱用(下記参照)のため、またはその後の嚥下の容易さのための粉砕。
(a)約マイナス80〜約プラス50℃(好ましくは約0〜約40℃、より好ましくは室温、例えば約15〜約30℃)の温度、約0.1〜約2バール(好ましくは気圧)の圧力、約5〜約95%(好ましくは約10〜約75%)の相対湿度、及び/又は約460ルクスのUV/可視光線への曝露を含む、長期間の(例えば、6ヶ月以上)通常の貯蔵条件下での一般的な物理化学的安定性。そのような条件下では、本明細書に記載された担体材料ネットワークは、上記のように約5%未満、例えば約1%未満が化学的に劣化/分解されていることが見出され得る。
(b)用いられる活性成分がオピオイド鎮痛剤である特に重要な場合、約15%未満の劣化をもたらす可能性があるので、意図的な乱用のための薬物の故意の生体外抽出(例えば、酸またはアルコール抽出、その後の注入によるか、または、本発明のセラミック構成要素の加熱及びその後のオピオイド中毒者による放出される蒸気または煙の吸入)の可能性を回避する、室温及び/又は高温(例えば、最大約200℃)での、酸性、アルカリ性、及び/又はアルコール性(例えばエタノール性)条件下での、一般的な物理化学的安定性。
(c)再び、用いられる活性成分がオピオイド鎮痛剤であり特に重要な場合、上の(b)で定義された活性成分の抽出の観点から、得られた粉末を直接吸引するオピオイド中毒者による機械的粉砕(grinding)または粉砕(milling)の可能性を低減する、一般的な物理的安定性。
(I)顆粒の押出(顆粒化が行われる場合)、
(II)球形化(湿った塊をふるいに通してペレットを生成すること)、
(III)乾燥、及び/又は
(IV)(必要であれば)加熱による硬化によって、
全ての場合において所定の技術を使用して、さらに適応され得る。
(i)少なくとも10%の気孔率を有する、本明細書に定義される固体多孔質の担体材料と、
(ii)担体材料の気孔内に位置する、本明細書に定義される送達可能な薬剤と、
を備える、物品を提供することと、
担体物質を加熱して、送達可能な薬剤を気化することと、を含む。
イブプロフェン(IOL Chemicals and Pharmaceuticals Ltd、インド)を含むセラミック円盤を、以下のように酸化アルミニウム(Al2O3、Keranova、スウェーデン)を用いて調製した。
ニコチン(ニコチン溶液(24mg/ml)、Ritch Group Ltd、英国)を含むセラミック円盤を、以下のように酸化アルミニウム(Al2O3、Keranova、スウェーデン)を用いて調製した。
酸化アルミニウム棒
酸化アルミニウムセラミック棒はCeramtech(スウェーデン)から得た、0.8mmの直径を有する4つのボアホール(軸方向に配向された)を含有する直径3mm及び長さ10mmのAl2O3円筒形の棒。
硫酸カルシウムアルファ半水和物(CaS)棒は、Bo Ehrlander AB(スウェーデン)から得た。成形されたシリコンゴムは、棒(直径6mm、長さ12mm)と硬貨(直径12mm、厚さ2mm)の両方の型として使用した。硫酸カルシウムを脱イオン水(0.4(w/w)の液体/粉末比)と混合して均質なペーストを形成し、ゴム型に充填した。ペーストを適用したとき、型を周囲条件下で少なくとも12時間固めて乾燥した。
試薬グレードのカオリナイト、ヒュームドシリカ(粒子サイズ7nm)、及び試薬グレードの水酸化ナトリウムは、Sigma−Aldrich(スウェーデン)から得た。ケイ酸ナトリウム溶液は、水酸化ナトリウム(NaOH)及びヒュームドシリカ(SiO2)を脱イオン水に溶解することによって製造した。カオリナイトを800℃で2時間加熱してメタカオリンを形成した。
純粋なニコチンUSP/EPは、BGP Healthcare pvt. Ltd.(インド)から得た。E−ジュース(LIQUA)18mg/ml及び24mg/mlを、Cigoteket(スウェーデン)から得た。E−ジュースは、プロピレングリコール中に溶解したニコチンの溶液である。18mg/ml未満の濃度は、適切な量の脱イオン水をe−ジュースに添加することによって達成した。
ニコチンの適用は、セラミック棒/硬貨の表面上にニコチンまたはニコチン溶液を一定範囲の濃度で浸漬または分注することによって達成された。
純粋なニコチン(液状)、純粋なE−ジュース、または水で希釈したE−ジュースを、棒または硬貨の表面上に分注した。ニコチンの適用後、試料を熱処理及び/又は分析の前に室温で24時間乾燥した。
棒を純粋なニコチンまたはニコチン溶液に浸漬した(正確な体積は測定しなかったが、棒は液体約100μlでちょうど覆った)。試料を室温で24時間浸漬し、その後、試料を熱処理及び/又は分析の前に24時間乾燥した。
オーブンWilfa EMK 218は、Wilfa、(ノルウェー)から得た。温度は約200℃に設定した。温度はMastechからのIR−温度計を用いて測定した。
全てのニコチン放出試験は、同じ分析方法に従って実施した。試料を50mlの脱イオン水を含有するビーカー内に浸した。24時間後、試料を取り出し、濾過した(気孔サイズ:0.2μm)。試料は、UV分光光度計によって219nmの波長で特徴付けられた。次に、試料中のニコチン量を計算した。参照試料と熱処理した試料における量の差は蒸発したと推定された。
酸化アルミニウム棒を、6mg/mlのニコチン溶液(希釈したe−ジュース)中に24時間浸漬した。熱処理前後に棒に残っているニコチン量を測定し、図3に示す。
硫酸カルシウム棒を純粋なニコチン中に24時間浸漬した。棒は、棒当たり約20mgのニコチンを吸収することができた。熱処理前後に棒に残っているニコチン量を測定し、図4に示す。
純粋なニコチン(20mg)をジオポリマー硬貨に分注した。熱処理前後に硬貨に残っているニコチン量を測定し、図6に示す。
材料
実施例3に記載したようにして、酸化アルミニウムセラミック棒及び硫酸カルシウム棒を得た。ニコチン及びニコチン溶液を供給して適用し、実施例3に記載したようにニコチンレベルを検出した。
試料は、Devex Mekatronik AB(スウェーデン)から得た試作電子タバコ装置(X−Cube II、Smoke)を用いて加熱した。この装置は、市販の電子タバコX−Cubeから派生している。
硫酸カルシウム棒を純粋なニコチン中に24時間浸漬し、電子タバコ装置で加熱(5×10秒)した。熱処理前後に棒に残っているニコチン量を測定し、図8に示す。
酸化アルミニウム(Al2O3)棒をニコチン溶液(18mg/ml)中に24時間浸漬し、装置で加熱(5×10秒)した。熱処理前後に棒に残っているニコチン量を測定し、図9に示す。
材料
実施例3に記載したようにして、硫酸カルシウム硬貨を得た。間接誘導試験のために、磁石を硬貨にかたどった。ニコチン及びニコチン溶液を供給して適用し、実施例3に記載したようにニコチンレベルを検出した。
電磁調理器用の金属プレートは、Hanestroem(スウェーデン)から得た。電磁調理器Wilfa ICP−2000は、Media Markt(スウェーデン)から得た。マグネット(10×1mm、サマリウムコバルト磁石、0.4kg引力)はfirst4magnets(英国)から得た。IR−温度計(MS6520A)はMastech(米国)から得た。
間接誘導による熱処理は、電磁調理器に金属プレートを載せて実施した。磁石を含有するセラミック硬貨を金属プレートに適用し、最大限の効果で加熱した(正確な温度は測定しなかった、図10を参照されたい)。
ニコチン溶液(50μl、18mg/ml)を硫酸カルシウム硬貨上に分注し、誘導プレート上で約1分間または約5分間加熱した。熱処理前後に硬貨に残っているニコチン量を測定し、図11に示す。ほとんどのニコチンは最初の1分内に放出された。
ニコチン溶液(50μl、18mg/ml)を硫酸カルシウム硬貨上に分注した。高温(少なくとも150℃)を得るために、プレートを約10秒間予熱した。取り出す前に、硬貨をプレート上で5秒間加熱した。抽出槽に入れる前に、硬貨を約15分間冷却して固めた。熱処理前後に硬貨に残っているニコチン量を測定し、図12に示す。
材料
酸化アルミニウムセラミック棒はCeramtech(スウェーデン)から得た、0.8mmの直径を有する4つのボアホール(軸方向に配向された)を含有する直径3mm及び長さ10mmのAl2O3円筒形の棒。スマトリプタンコハク酸塩をSMS Pharmaceuticals Limited、インド、から得た。
スマトリプタンコハク酸塩の適用は、20mg/mlの濃度を有するコハク酸スマトリプタン溶液中にAl2O3棒を浸漬することによって達成した。溶液の体積は約100μlであったが、正確には測定されなかった。体積は棒を完全に浸すのに十分であった。試料を室温で24時間浸漬し、その後、試料を熱処理及び/又は分析の前に24時間乾燥した。
オーブンWilfa EMK 218は、Wilfa、(ノルウェー)から得た。温度は約300℃に設定した。温度はMastech、米国からのIR−温度計を用いて測定した。棒をオーブン中で、0〜15分の期間の間、加熱した。
全てのスマトリプタン放出試験は、同じ分析方法に従って実施した。棒を50mlの脱イオン水を含有するビーカーに浸した。24時間後、水の試料を取り出し、濾過した(気孔サイズ:0.2μm)。試料は、282nmの波長でUV分光光度測定によって特徴付けられた。次に、試料中のスマトリプタンコハク酸塩量を計算した。参照試料は、熱処理前に装填されたスマトリプタンコハク酸塩量を表す。熱処理した試料と参照試料中に検出したスマトリプタンコハク酸塩量の差は、熱処理中に蒸発したスマトリプタンコハク酸塩量を表す。
熱処理前後に棒中に残っているスマトリプタンコハク酸塩の量を測定し、図13に示す。
試料調製
硫酸カルシウムアルファ半水和物(CaS)は、Bo Ehrlander AB(スウェーデン)から得た。塩酸クロニジンは、PCAS(フィンランド)から得た。成形されたシリコンゴムは、硬貨(直径12mm、厚さ2mm)の型として使用した。硫酸カルシウムを塩酸クロニジン(0.07gの塩酸クロニジン/gの硫酸カルシウム)の粉末及び脱イオン水(0.4(w/w)の液体/粉末比)と混合して均質なペーストを形成し、ゴム型に充填するために使用した。ペーストを適用したら、型を周囲条件下で少なくとも12時間固めて乾燥した。
オーブンWilfa EMK 218は、Wilfa(ノルウェー)から得た。オーブン温度は約250℃に設定した。温度はMastech(米国)からのIR−温度計を用いて測定した。硬貨をオーブン中で、0〜15分の期間の間、加熱した。
各硬貨を秤量し、200mlの脱イオン水を含有するビーカーに浸した。24時間後、液体の試料を取り出し、濾過した(気孔サイズ:0.2μm)。試料は、アセトニトリル/リン酸の移動相、pH3(11/89)を有するGenesis C18分析カラム4μm(100×2.1mm i.d.)を有するShimadzu LC−2030(ドイツ)HPLCシステムによって特徴付けられた。波長は220nmに設定した。
塩酸クロニジンを硫酸カルシウム(0.07g塩酸クロニジン/g硫酸カルシウム)と共に混合して硬貨を形成した。硬貨は約17mgの塩酸クロニジン(1硬貨は約0.3gの重さであった)を含有していた。硬貨は、上で記載されたように加熱した(または参照試料の場合には加熱されなかった)。熱処理前後に硬貨中に残っている塩酸クロニジンの量を測定し、図14に示す。熱処理後の試料中に残っている塩酸クロニジン量が少ないため、加熱した場合、塩酸クロニジンのほとんど全てが最初の15分内で放出された。
試料調製
硫酸カルシウムアルファ半水和物(CaS)は、Bo Ehrlander AB(スウェーデン)から得た。塩酸クロニジンは、PCAS(フィンランド)から得た。成形されたシリコンゴムは、硬貨(直径12mm、厚さ2mm)の型として使用した。硫酸カルシウムを脱イオン水(0.4(w/w)の液体/粉末比)と混合して均質なペーストを形成し、ゴム型を充填するために使用した。ペーストを適用したとき、型を周囲条件下で少なくとも12時間固めて乾燥した。
オーブンWilfa EMK 218は、Wilfa、(ノルウェー)から得た。温度は約250℃に設定した。温度はMastech、(米国)からのIR−温度計を用いて測定した。硬貨をオーブン中で、0〜15分の期間の間、加熱した。
各硬貨を秤量し、200mlの脱イオン水を含有するビーカーに浸した。24時間後、水の試料を取り出し、濾過した(気孔サイズ:0.2μm)。試料は、アセトニトリル/リン酸の移動相、pH3(11/89)を有するGenesis C18分析カラム4μm(100×2.1mm i.d.)を有するShimadzu LC−2030(ドイツ)HPLCシステムによって特徴付けられた。波長は220nmに設定した。
塩酸クロニジン溶液(50μl、5mg/ml)を硫酸カルシウム硬貨上に分注した。硬貨は、上で記載されたように加熱した(または参照試料の場合には加熱されなかった)。熱処理前後に硬貨中に残っている塩酸クロニジンの量を測定し、図15に示す。加熱中、硬貨中に存在する塩酸クロニジン量は、経時的に著しく減少した。
試料調製
硫酸カルシウムアルファ半水和物(CaS)は、Bo Ehrlander AB(スウェーデン)から得た。成形されたシリコンゴムは、硬貨(直径12mm、厚さ2mm)の型として使用した。硫酸カルシウムを、ニコチンの5または20mg/mlの濃度を有するニコチン溶液(0.4(w/w)の液体/粉末比)と混合して均質なペーストを形成し、ゴム型に充填した。ペーストを適用したら、型を周囲条件下で少なくとも12時間固めて乾燥した。
オーブンWilfa EMK 218は、Wilfa、(ノルウェー)から得た。温度は約200℃に設定した。温度はMastech、(米国)からのIR−温度計を用いて測定した。硬貨をオーブン中で、0〜15分の期間の間、加熱した。
各コインを50mlの脱イオン水を含有するビーカー内に浸した。24時間後、試料を取り出し、濾過した(気孔サイズ:0.2μm)。試料は、UV分光光度計によって219nmの波長で特徴付けられた。次に、試料中のニコチン量を計算した。参照試料と熱処理した試料中の量の差は、熱処理中に蒸発したニコチン量を表す。
2つの異なるニコチン溶液を使用して硬貨を作製した。5mg/ml及び20mg/mlである。両方のバッチで0.4(w/w)の同じ液体/粉末比を使用した。硬貨は約180μg(5mg/mlのニコチン溶液と混合した硬貨の場合)及び390μg(20mg/mlのニコチン溶液と混合した硬貨の場合)を含有していた。熱処理前後に硬貨中に残っているニコチン量を測定し、図16に示す。
試料調製
硫酸カルシウムアルファ半水和物(CaS)は、Bo Ehrlander AB(スウェーデン)から得た。スマトリプタンコハク酸塩は、SMS Pharmaceuticals Limited、インドから得た。成形されたシリコンゴムは、硬貨(直径12mm、厚さ2mm)の型として使用した。硫酸カルシウムをスマトリプタンコハク酸塩(0.07gスマトリプタンコハク酸塩/g硫酸カルシウム)及び脱イオン水(0.4(w/w)の液体/粉末比)と混合して均質なペーストを形成し、ゴム型に充填した。ペーストを適用したとき、型を周囲条件下で少なくとも12時間固めて乾燥した。
オーブンWilfa EMK 218は、Wilfa、(ノルウェー)から得た。温度は約250℃に設定した。温度はMastech、(米国)からのIR−温度計を用いて測定した。硬貨をオーブン中で、0〜15分の期間の間、加熱した。
硬貨を50mlの脱イオン水を含有するビーカーに浸した。24時間後、水の試料を取り出し、濾過した(気孔サイズ:0.2μm)。試料は、282nmの波長でUV分光光度測定によって特徴付けられた。次に、試料中のスマトリプタンコハク酸塩量を計算した。
熱処理前後に硬貨中に残っているスマトリプタンコハク酸塩の量を測定し、図17に示す。熱処理後の試料中に残っているスマトリプタンコハク酸塩量が少ないため、加熱した場合、スマトリプタンコハク酸塩のほとんど全てが最初の15分内で放出された。
Claims (22)
- 送達可能な薬剤をエアロゾルまたは蒸気の形態で使用者に送達するための装置であって、少なくとも10%の気孔率を有する固体多孔質の担体材料と、前記担体材料の気孔内に位置する送達可能な薬剤と、を含み、前記装置が、前記担体材料を加熱し、前記送達可能な薬剤を気化するように動作可能である、装置。
- 前記担体材料が、約20%〜約70%の気孔率を有する、請求項1に記載の装置。
- 前記担体材料中の平均気孔サイズが、約0.1μm〜約500μm、好ましくは約0.2μm〜約200μmである、請求項1または請求項2に記載の装置。
- 前記送達可能な薬剤が、主に前記担体材料の前記気孔内に位置する、請求項1〜3のいずれか一項に記載の装置。
- 前記担体材料が、1つ以上の化学結合されたセラミック材料、1つ以上のジオポリマー材料、または1つ以上の金属をベースにしている、請求項1〜4のいずれか一項に記載の装置。
- 前記担体材料が、
(i)アルミノケイ酸塩前駆体材料を水性アルカリ性液体と反応させるプロセスによって得ることができる材料と、
(ii)リン酸カルシウム、硫酸カルシウム、炭酸カルシウム、ケイ酸カルシウム、アルミン酸カルシウム、炭酸マグネシウム、ケイ酸アルミニウム、及びそれらの組み合わせと、からなる群より選択される、請求項5に記載の装置。 - 前記担体材料が、(i)硫酸カルシウム、リン酸カルシウム、ケイ酸カルシウム、炭酸カルシウム、アルミン酸カルシウム、炭酸マグネシウム、もしくはそれらの組み合わせからなる群より選択されるか、または(ii)カオリン、ディッカイト、ハロイサイト、ナクライト、ゼオライト、イライト、脱ヒドロキシル化ゼオライト、脱ヒドロキシル化ハロイサイト及びメタカオリンからなる群より選択されるアルミノケイ酸塩前駆体材料を、水性アルカリ性液体と、任意でシリカ源の存在下で反応させるプロセスによって得ることができる材料である、請求項5に記載の装置。
- 前記送達可能な薬剤が、活性医薬成分であり、前記活性医薬成分は、任意に、降圧剤、鎮静剤、催眠剤および鎮痛剤からなる群より選択される、請求項1〜7のいずれか一項に記載の装置。
- 前記活性医薬成分が、オピオイド鎮痛剤である、請求項8に記載の装置。
- 前記オピオイド鎮痛剤が、モルヒネ、オキシコドン、ブプレノルフィン、アルフェンタニル、スフェンタニル、レミフェンタニル及びフェンタニルから選択される、請求項9に記載の装置。
- 前記活性医薬成分が、ニコチンまたはその薬学的に許容される塩である、請求項8に記載の装置。
- 前記担体材料及び前記送達可能な薬剤が、交換可能なカートリッジ内で共に提供される、請求項1〜11のいずれか一項に記載の装置。
- 前記交換可能なカートリッジが、基本的に前記担体材料と、前記送達可能な薬剤と、任意で、導電性材料の粒子並びに/又は蒸発促進剤、香料および味増強剤からなる群より選択される1つ以上の物質と、からなる、請求項12に記載の装置。
- 前記担体材料を加熱するように動作可能な加熱素子をさらに備える、請求項1〜13のいずれか一項に記載の装置。
- 前記加熱素子が、前記担体材料の近位に位置する、請求項14に記載の装置。
- 吸入装置で使用するためのカートリッジまたは単位用量製剤であって、前記カートリッジまたは単位用量製剤が、
(i)任意で、請求項1〜7のいずれか一項に定義される、1つ以上の化学結合されたセラミック材料または1つ以上のジオポリマー材料をベースにした、少なくとも10%の気孔率を有する固体多孔質の担体材料と、
(ii)前記担体材料の前記気孔内に位置する、請求項1または8〜11のいずれか一項に定義される送達可能な薬剤と、を含有する、カートリッジまたは単位用量製剤。 - 導電性材料の粒子をさらに含有する、請求項16に記載のカートリッジまたは単位用量製剤。
- 前記送達可能な薬剤が活性医薬成分であり、前記装置、前記カートリッジ、または単位用量製剤が、十分な量の前記活性医薬成分を含有して、1単位用量以下の前記活性医薬成分を前記使用者に提供する、請求項1〜15のいずれか一項に記載の装置、または請求項16もしくは請求項17に記載のカートリッジもしくは単位用量製剤。
- 送達可能な薬剤を蒸気またはエアロゾルの形態で使用者に送達する方法であって、その方法は、
(a)
(i)請求項1〜7のいずれか一項に定義される少なくとも10%の気孔率を有する固体多孔質の担体材料と、
(ii)請求項1または8〜11のいずれか一項に定義される送達可能な薬剤と、を備え、前記送達可能な薬剤が前記担体材料の前記気孔内に位置する物品を提供することと、
(b)前記担体材料を加熱して、前記送達可能な薬剤を気化することと、を含む、方法。 - 請求項8に定義される吸入装置を使用して、活性医薬成分を、エアロゾルまたは蒸気の形態で、疾患に罹患しているか、または罹患しやすい人に送達することを含み、前記活性医薬成分が前記疾患を治療または予防する、疾患を治療または予防する方法。
- 請求項9に定義される吸入装置を使用して、1つ以上のオピオイド鎮痛剤を、エアロゾルまたは蒸気の形態で、疼痛に罹患しているか、または罹患しやすい人に送達することを含む、疼痛の治療方法。
- 請求項11に定義される吸入装置を使用して、ニコチンを、エアロゾルまたは蒸気の形態で、ニコチン依存症の症状を患っている人に送達することを含む、ニコチン依存症を治療する方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1603463.9A GB201603463D0 (en) | 2016-02-29 | 2016-02-29 | Devices for evaporation and inhalation of active agents |
GB1603463.9 | 2016-02-29 | ||
GB1702805.1 | 2017-02-21 | ||
GBGB1702805.1A GB201702805D0 (en) | 2017-02-21 | 2017-02-21 | Devices for evaporation and inhalation of active agents |
PCT/GB2017/050531 WO2017149287A1 (en) | 2016-02-29 | 2017-02-28 | Devices for evaporation and inhalation of active agents |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019511920A true JP2019511920A (ja) | 2019-05-09 |
JP7042747B2 JP7042747B2 (ja) | 2022-03-28 |
Family
ID=58455336
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018545487A Active JP7042747B2 (ja) | 2016-02-29 | 2017-02-28 | 活性薬剤の蒸発及び吸入装置 |
JP2018545441A Active JP7179245B2 (ja) | 2016-02-29 | 2017-02-28 | ニコチンの蒸発及び吸入装置 |
JP2022095409A Withdrawn JP2022137035A (ja) | 2016-02-29 | 2022-06-14 | ニコチンの蒸発及び吸入装置 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018545441A Active JP7179245B2 (ja) | 2016-02-29 | 2017-02-28 | ニコチンの蒸発及び吸入装置 |
JP2022095409A Withdrawn JP2022137035A (ja) | 2016-02-29 | 2022-06-14 | ニコチンの蒸発及び吸入装置 |
Country Status (11)
Country | Link |
---|---|
US (3) | US20190046743A1 (ja) |
EP (2) | EP3423135A1 (ja) |
JP (3) | JP7042747B2 (ja) |
KR (2) | KR20180127375A (ja) |
CN (2) | CN109069770A (ja) |
AU (2) | AU2017227070B2 (ja) |
CA (2) | CA3016215A1 (ja) |
ES (1) | ES2965015T3 (ja) |
IL (2) | IL261469A (ja) |
RU (2) | RU2743447C2 (ja) |
WO (2) | WO2017149288A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019515700A (ja) * | 2016-02-29 | 2019-06-13 | エンプリキュア・アクチエボラゲット | ニコチンの蒸発及び吸入装置 |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160345631A1 (en) | 2005-07-19 | 2016-12-01 | James Monsees | Portable devices for generating an inhalable vapor |
US10279934B2 (en) | 2013-03-15 | 2019-05-07 | Juul Labs, Inc. | Fillable vaporizer cartridge and method of filling |
US10638792B2 (en) | 2013-03-15 | 2020-05-05 | Juul Labs, Inc. | Securely attaching cartridges for vaporizer devices |
DE202014011309U1 (de) | 2013-12-23 | 2019-03-29 | Juul Labs Uk Holdco Limited | Systeme für eine Verdampfungsvorrichtung |
US10076139B2 (en) | 2013-12-23 | 2018-09-18 | Juul Labs, Inc. | Vaporizer apparatus |
US10159282B2 (en) | 2013-12-23 | 2018-12-25 | Juul Labs, Inc. | Cartridge for use with a vaporizer device |
US10058129B2 (en) | 2013-12-23 | 2018-08-28 | Juul Labs, Inc. | Vaporization device systems and methods |
USD825102S1 (en) | 2016-07-28 | 2018-08-07 | Juul Labs, Inc. | Vaporizer device with cartridge |
US20160366947A1 (en) | 2013-12-23 | 2016-12-22 | James Monsees | Vaporizer apparatus |
USD842536S1 (en) | 2016-07-28 | 2019-03-05 | Juul Labs, Inc. | Vaporizer cartridge |
RU2709926C2 (ru) | 2014-12-05 | 2019-12-23 | Джуул Лэбз, Инк. | Контроль калиброванной дозы |
EP3413960B1 (en) | 2016-02-11 | 2021-03-31 | Juul Labs, Inc. | Fillable vaporizer cartridge and method of filling |
US10405582B2 (en) | 2016-03-10 | 2019-09-10 | Pax Labs, Inc. | Vaporization device with lip sensing |
USD849996S1 (en) | 2016-06-16 | 2019-05-28 | Pax Labs, Inc. | Vaporizer cartridge |
USD836541S1 (en) | 2016-06-23 | 2018-12-25 | Pax Labs, Inc. | Charging device |
USD851830S1 (en) | 2016-06-23 | 2019-06-18 | Pax Labs, Inc. | Combined vaporizer tamp and pick tool |
EP3550998A1 (en) | 2016-12-12 | 2019-10-16 | VMR Products LLC | Vaporizer cartridge |
AU2018262708B2 (en) * | 2017-05-04 | 2021-06-03 | Nanologica Ab | A process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual and/or pharyngeal delivery |
GB201714412D0 (en) * | 2017-09-07 | 2017-10-25 | Emplicure Ab | Evaporation devices containing plant material |
USD887632S1 (en) | 2017-09-14 | 2020-06-16 | Pax Labs, Inc. | Vaporizer cartridge |
GB201718032D0 (en) * | 2017-11-01 | 2017-12-13 | British American Tobacco Investments Ltd | Aerosolisable gel |
DE102018100749A1 (de) * | 2018-01-15 | 2019-07-18 | Schott Ag | Poröse Sinterkörper zur Verwendung als Flüssigkeitsspeicher und Verdampfer |
JP6371928B1 (ja) * | 2018-02-23 | 2018-08-08 | 株式会社 東亜産業 | 電子タバコ用充填物およびそれを用いた電子タバコカートリッジ |
JP2021525093A (ja) | 2018-05-31 | 2021-09-24 | ジェイティー インターナショナル エス.エイ.JT International S.A. | エアロゾル発生物品、エアロゾル発生システム、及びフレーバー付きエアロゾルを発生するための方法 |
US11413409B2 (en) | 2018-09-12 | 2022-08-16 | Juul Labs, Inc. | Vaporizer including positive temperature coefficient of resistivity (PTCR) heating element |
US11553734B2 (en) | 2018-11-08 | 2023-01-17 | Juul Labs, Inc. | Cartridges for vaporizer devices |
WO2020194122A1 (en) * | 2019-03-24 | 2020-10-01 | Buzzelet Development And Technologies Ltd. | Cannabis inhalation products and methods of production thereof |
CN110876494B (zh) * | 2019-11-26 | 2021-10-01 | 深圳麦克韦尔科技有限公司 | 一种雾化器及其陶瓷雾化芯和陶瓷雾化芯制备方法 |
WO2021194911A1 (en) * | 2020-03-22 | 2021-09-30 | Metcalf Douglas G | Systems and methods to administer pharmaceuticals |
US20220000178A1 (en) * | 2020-07-01 | 2022-01-06 | Nicoventures Trading Limited | 3d-printed substrate for aerosol delivery device |
USD1028336S1 (en) | 2021-06-22 | 2024-05-21 | Pax Labs, Inc. | Vaporizer cartridge |
WO2023089771A1 (ja) * | 2021-11-19 | 2023-05-25 | 日本たばこ産業株式会社 | ニコチン含有組成物におけるニコチン分布の分析方法 |
GB2620110A (en) * | 2022-06-15 | 2024-01-03 | Amplicon Ab | Alkaline intraoral products |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009537119A (ja) * | 2006-05-16 | 2009-10-29 | ハン、リー | エアロゾル電子たばこ |
WO2011146174A2 (en) * | 2010-05-15 | 2011-11-24 | Nathan Andrew Terry | Volume liquid storage reservoir in a personal vaporizing inhaler |
JP2013536875A (ja) * | 2010-09-07 | 2013-09-26 | オレクソ・アクチエボラゲット | 経皮薬物投与デバイス |
JP2014528764A (ja) * | 2011-08-11 | 2014-10-30 | ウィスプライト テクノロジーズ インコーポレイテッド | 携帯用蒸気発生電子装置および蒸気発生方法 |
WO2015177252A1 (en) * | 2014-05-21 | 2015-11-26 | Philip Morris Products S.A. | Inductively heatable tobacco product |
CN112107027A (zh) * | 2020-10-19 | 2020-12-22 | 江苏中烟工业有限责任公司 | 一种降低卷烟烟气中氢氰酸的功能化地聚合物材料及其应用 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4303083A (en) | 1980-10-10 | 1981-12-01 | Burruss Jr Robert P | Device for evaporation and inhalation of volatile compounds and medications |
JP2702953B2 (ja) | 1988-01-30 | 1998-01-26 | オリンパス光学工業株式会社 | 薬液含浸セラミックス |
WO1998023556A1 (fr) * | 1996-11-25 | 1998-06-04 | Kabushiki Kaisya Advance | Procede de production de ceramiques |
SE9704643D0 (sv) * | 1997-12-12 | 1997-12-12 | Astra Ab | Inhalation apparatus and method |
US5996589A (en) | 1998-03-03 | 1999-12-07 | Brown & Williamson Tobacco Corporation | Aerosol-delivery smoking article |
US20030118641A1 (en) | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
US20080038363A1 (en) * | 2001-05-24 | 2008-02-14 | Zaffaroni Alejandro C | Aerosol delivery system and uses thereof |
JP2008506700A (ja) | 2004-07-13 | 2008-03-06 | アルテアーナノ,インコーポレーテッド | 薬物の制御された放出のためのセラミック構造体 |
EP1768651A4 (en) * | 2004-07-13 | 2008-09-10 | Altairnano Inc | CERAMIC STRUCTURES FOR THE PREVENTION OF MEDICINAL USE |
US20060210634A1 (en) | 2005-03-04 | 2006-09-21 | Moerck Rudi E | Ceramic structures for controlled release of biologically active substances |
CN101489686A (zh) * | 2006-06-09 | 2009-07-22 | 菲利普莫里斯生产公司 | 间接加热的毛细管气雾剂发生器 |
US20090061003A1 (en) * | 2007-03-28 | 2009-03-05 | Doxa Ab | Carriers for drug delivery |
GB0709541D0 (en) * | 2007-05-17 | 2007-06-27 | Jagotec Ag | Pharmaceutical excipient |
ES2660674T3 (es) * | 2009-03-04 | 2018-03-23 | Emplicure Ab | Formulación resistente al abuso |
MX2011011829A (es) | 2009-05-08 | 2012-02-21 | Orexo Ab | Composicion para suministro sostenido de farmaco que comprende un aglutinante geopolimerico. |
TWI546023B (zh) * | 2011-10-27 | 2016-08-21 | 菲利浦莫里斯製品股份有限公司 | 具有氣溶膠生產控制之電操作氣溶膠產生系統 |
US20130220314A1 (en) * | 2012-02-29 | 2013-08-29 | General Electric Company | Medical vaporizer with porous vaporization element |
US9814262B2 (en) | 2012-07-11 | 2017-11-14 | Sis Resources, Ltd. | Hot-wire control for an electronic cigarette |
US20150074554A1 (en) | 2013-01-18 | 2015-03-12 | Panasonic Intellectual Property Corporation Of America | Content presentation method and program |
MY189478A (en) | 2013-02-22 | 2022-02-16 | Altria Client Services Llc | Electronic smoking article |
US20150075546A1 (en) | 2013-07-12 | 2015-03-19 | Stoicheion Technology LLC | Controller With Network Access and Unique ID for Personal Electronic Devices |
US10172387B2 (en) | 2013-08-28 | 2019-01-08 | Rai Strategic Holdings, Inc. | Carbon conductive substrate for electronic smoking article |
US20150209530A1 (en) | 2013-10-14 | 2015-07-30 | Jackie L. White | Substrates for vaporizing and delivering an aerosol agent |
US9016274B1 (en) | 2013-10-14 | 2015-04-28 | Jackie L. White | Devices for vaporizing and delivering an aerosol agent |
CN103734916A (zh) | 2014-01-16 | 2014-04-23 | 深圳市聚东方科技有限公司 | 基于蓝牙4.0技术的物联网智能电子烟 |
US20150335070A1 (en) | 2014-05-20 | 2015-11-26 | R.J. Reynolds Tobacco Company | Electrically-powered aerosol delivery system |
EP3162778B1 (en) | 2014-06-16 | 2019-08-07 | Shenzhen Smoore Technology Limited | Method for preparing porous ceramics |
EP3009019B1 (en) * | 2014-10-17 | 2019-05-01 | Fontem Holdings 1 B.V. | Cartridge having a liquid transporting element for uses with an electronic smoking device |
GB201503961D0 (en) | 2015-03-09 | 2015-04-22 | Emplicure Ab | A transdermal drug administration device |
CN104886785B (zh) | 2015-06-15 | 2017-09-22 | 湖北中烟工业有限责任公司 | 一种电子烟多孔陶瓷雾化发热组件 |
CN105394816B (zh) | 2015-10-22 | 2018-12-21 | 深圳麦克韦尔股份有限公司 | 电子烟及其雾化组件和雾化元件 |
CN105755434B (zh) | 2016-02-26 | 2018-10-26 | 北京师范大学 | 一种基于离子束技术的新型电子烟雾化器装置中导电层的制造方法和设备 |
CN109069770A (zh) * | 2016-02-29 | 2018-12-21 | 埃姆普里居公司 | 用于蒸发和吸入尼古丁的装置 |
-
2017
- 2017-02-28 CN CN201780025007.0A patent/CN109069770A/zh active Pending
- 2017-02-28 ES ES17714509T patent/ES2965015T3/es active Active
- 2017-02-28 CN CN201780024980.0A patent/CN109069769A/zh active Pending
- 2017-02-28 CA CA3016215A patent/CA3016215A1/en active Pending
- 2017-02-28 EP EP17714510.9A patent/EP3423135A1/en not_active Withdrawn
- 2017-02-28 JP JP2018545487A patent/JP7042747B2/ja active Active
- 2017-02-28 AU AU2017227070A patent/AU2017227070B2/en not_active Ceased
- 2017-02-28 JP JP2018545441A patent/JP7179245B2/ja active Active
- 2017-02-28 US US16/080,867 patent/US20190046743A1/en active Pending
- 2017-02-28 KR KR1020187027965A patent/KR20180127375A/ko not_active Application Discontinuation
- 2017-02-28 RU RU2018132578A patent/RU2743447C2/ru active
- 2017-02-28 WO PCT/GB2017/050533 patent/WO2017149288A1/en active Application Filing
- 2017-02-28 EP EP17714509.1A patent/EP3423134B1/en active Active
- 2017-02-28 RU RU2018132401A patent/RU2743446C2/ru active
- 2017-02-28 WO PCT/GB2017/050531 patent/WO2017149287A1/en active Application Filing
- 2017-02-28 US US16/080,881 patent/US11202871B2/en active Active
- 2017-02-28 CA CA3016205A patent/CA3016205A1/en active Pending
- 2017-02-28 KR KR1020187027966A patent/KR20180128917A/ko not_active Application Discontinuation
- 2017-02-28 AU AU2017227071A patent/AU2017227071B2/en not_active Ceased
-
2018
- 2018-08-29 IL IL261469A patent/IL261469A/en unknown
- 2018-08-29 IL IL261462A patent/IL261462A/en unknown
-
2021
- 2021-11-15 US US17/526,571 patent/US20220126030A1/en active Pending
-
2022
- 2022-06-14 JP JP2022095409A patent/JP2022137035A/ja not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009537119A (ja) * | 2006-05-16 | 2009-10-29 | ハン、リー | エアロゾル電子たばこ |
WO2011146174A2 (en) * | 2010-05-15 | 2011-11-24 | Nathan Andrew Terry | Volume liquid storage reservoir in a personal vaporizing inhaler |
JP2013536875A (ja) * | 2010-09-07 | 2013-09-26 | オレクソ・アクチエボラゲット | 経皮薬物投与デバイス |
JP2014528764A (ja) * | 2011-08-11 | 2014-10-30 | ウィスプライト テクノロジーズ インコーポレイテッド | 携帯用蒸気発生電子装置および蒸気発生方法 |
WO2015177252A1 (en) * | 2014-05-21 | 2015-11-26 | Philip Morris Products S.A. | Inductively heatable tobacco product |
CN112107027A (zh) * | 2020-10-19 | 2020-12-22 | 江苏中烟工业有限责任公司 | 一种降低卷烟烟气中氢氰酸的功能化地聚合物材料及其应用 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019515700A (ja) * | 2016-02-29 | 2019-06-13 | エンプリキュア・アクチエボラゲット | ニコチンの蒸発及び吸入装置 |
Also Published As
Publication number | Publication date |
---|---|
KR20180128917A (ko) | 2018-12-04 |
US20220126030A1 (en) | 2022-04-28 |
AU2017227070A1 (en) | 2018-10-04 |
IL261462A (en) | 2018-10-31 |
RU2743446C2 (ru) | 2021-02-18 |
RU2018132578A (ru) | 2020-04-01 |
CN109069769A (zh) | 2018-12-21 |
AU2017227071B2 (en) | 2022-03-31 |
RU2018132401A (ru) | 2020-04-02 |
RU2743447C2 (ru) | 2021-02-18 |
JP2019515700A (ja) | 2019-06-13 |
US20190038553A1 (en) | 2019-02-07 |
EP3423135A1 (en) | 2019-01-09 |
US11202871B2 (en) | 2021-12-21 |
JP2022137035A (ja) | 2022-09-21 |
KR20180127375A (ko) | 2018-11-28 |
JP7179245B2 (ja) | 2022-11-29 |
JP7042747B2 (ja) | 2022-03-28 |
CN109069770A (zh) | 2018-12-21 |
AU2017227071A1 (en) | 2018-09-27 |
US20190046743A1 (en) | 2019-02-14 |
CA3016205A1 (en) | 2017-09-08 |
AU2017227070B2 (en) | 2022-03-31 |
ES2965015T3 (es) | 2024-04-10 |
EP3423134B1 (en) | 2023-08-30 |
EP3423134A1 (en) | 2019-01-09 |
WO2017149287A1 (en) | 2017-09-08 |
RU2018132401A3 (ja) | 2020-06-18 |
WO2017149288A1 (en) | 2017-09-08 |
CA3016215A1 (en) | 2017-09-08 |
RU2018132578A3 (ja) | 2020-06-18 |
IL261469A (en) | 2018-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7042747B2 (ja) | 活性薬剤の蒸発及び吸入装置 | |
EP3678500B1 (en) | Evaporation devices containing plant material | |
CN102341096B (zh) | 新型抗滥用制剂 | |
JP5843864B2 (ja) | 経皮薬物投与デバイス | |
JP2018513121A (ja) | 経皮薬物投与デバイス | |
JP2012526091A (ja) | ジオポリマー結合剤を含む持続薬物送達用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200227 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210319 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210406 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210702 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211006 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220308 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220315 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7042747 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |